Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Tonsillar Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Laryngeal Neoplasms 1Kidney Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Large Cell 1Carcinoma 1Breast Neoplasms 1Brain Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Rituximab 58Cyclophosphamide 40fludarabine phosphate 27fludarabine 21Lenalidomide 19Mycophenolic Acid 17idelalisib 16Antilymphocyte Serum 16Cyclosporine 15Tacrolimus 13Radiotherapy 13Filgrastim 13venetoclax 12umbralisib 12Whole-Body Irradiation 12Busulfan 12Bendamustine Hydrochloride 12ublituximab 11ibrutinib 11Methotrexate 11Peripheral Blood Stem Cell Transplantation 10Alemtuzumab 10obinutuzumab 9Melphalan 9Chlorambucil 8Bortezomib 8thymoglobulin 7ofatumumab 7Etoposide 7Clofarabine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Leukemia, Lymphocytic, Chronic, B-Cell × motexafin gadolinium × Clear all
NCT00076401 2014-06-26

A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)

Pharmacyclics LLC.

Phase 2 Terminated
27 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00100711 2014-05-23

Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Pharmacyclics LLC.

Phase 2 Terminated
27 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡